Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders

被引:49
|
作者
Schad, Karin [1 ]
Conzett, Katrin Baumann [1 ]
Zipser, Marie C. [1 ]
Enderlin, Valerie [1 ]
Kamarashev, Jivko [1 ]
French, Lars E. [1 ]
Dummer, Reinhard [1 ]
机构
[1] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland
关键词
GROWTH-FACTOR RECEPTOR; CANCER-PATIENTS; MECHANISMS; CETUXIMAB; MELANOMA; EXPRESS;
D O I
10.1158/1078-0432.CCR-09-1766
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Raf/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signaling pathway is constitutively activated in melanoma. AZD6244 blocks MEK1/2, inhibiting ERK phosphorylation. We focus on associated cutaneous toxicity and we attempt to understand the underlying pathophysiology and design treatment strategies. Experimental Design: Dermatologic conditions of 22 patients with unresectable melanoma stage III/IV in a phase II trial were evaluated. Thirteen patients received AZD6244 initially, and nine patients were treated with AZD6244 following tumor progression with temozolomide. Biopsies were compared with matched controls in normal skin. Immunohistochemistry was performed. Half-side treatment of acute skin toxicity compared therapeutic options. Results: Nineteen of 22 (86%) AZD6244-treated patients presented with cutaneous eruptions. Seventeen patients (77%) developed acute papulopustular rash. Chronic skin changes included xerosis, paronychia, and fissured fingertips, resembling cutaneous toxicity of epidermal growth factor receptor inhibition. In addition, we observed reduced pigmentation of hair and skin. Histology of acute skin lesions revealed a significant increase of apoptotic keratinocytes (P = 0.0008), focal neutrophilic infiltrates, destruction of the adnexal structures by neutrophils, and reduced cytokeratins. A significant proliferation shift from basal to suprabasal keratinocytes was shown in acute and chronic lesions. The number and viability of melanocytes was not affected. Corticosteroids plus antibacterial topical therapy ameliorate acute skin toxicity. Conclusions: AZD6244-associated skin reactions partly overlap with those observed upon epidermal growth factor receptor inhibition. Additionally, pigmentation of skin and hair is affected. The interruption of the MEK signaling pathway results in an acute keratinocyte stress response with disturbed epidermal homeostasis, inflammation, and tissue damage. Chronic adaptation controls inflammatory tissue damage but leads to cutaneous malfunctions that explain chronic skin toxicity. Clin Cancer Res; 16(3); 1058-64. (C) 2010 AACR.
引用
收藏
页码:1058 / 1064
页数:7
相关论文
共 50 条
  • [21] Induction of mitogen-activated protein kinase phosphatase 1 by the stress-activated protein kinase signaling pathway but not by extracellular signal-regulated kinase in fibroblasts
    Bokemeyer, D
    Sorokin, A
    Yan, MH
    Ahn, NG
    Templeton, DJ
    Dunn, MJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (02) : 639 - 642
  • [22] Different Effects of Amlodipine and Enalapril on the Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase–Extracellular Signal-Regulated Kinase Pathway for Induction of Vascular Smooth Muscle Cell Differentiation In Vivo
    Seiji Umemoto
    Shinji Kawahara
    Ryo Hashimoto
    Kyoko Umeji
    Susumu Matsuda
    Masakazu Tanaka
    Makoto Kubo
    Masunori Matsuzaki
    Hypertension Research, 2006, 29 : 179 - 186
  • [23] Genetic variation in the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway affects contact hypersensitivity responses
    Legrand, Julien M. D.
    Roy, Edwige
    Baz, Batoul
    Mukhopadhyay, Pamela
    Wong, Ho Yi
    Ram, Ramesh
    Morahan, Grant
    Walker, Graeme
    Khosrotehrani, Kiarash
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 142 (03) : 981 - 984
  • [24] Isolation of the protein kinase TAO2 and identification of its mitogen-activated protein kinase/extracellular signal-regulated kinase kinase binding domain
    Chen, Z
    Hutchison, M
    Cobb, MH
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (40) : 28803 - 28807
  • [25] PEDIATRICS CUTANEOUS REACTIONS IN PATIENT TREATED WITH THE MITOGEN-ACTIVATED PROTEIN KINASE EXTRACELLULAR SIGNAL-REGULATED KINASE INHIBITOR TRAMETINIB
    Gluck, Mirit
    Ben-Amitai, Dan
    Friedland, Rivka
    Toledano, Helen
    NEURO-ONCOLOGY, 2022, 24 : 155 - 155
  • [26] BimEL is an important determinant for induction of anoikis sensitivity by mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitors
    Fukazawa, H
    Noguchi, K
    Masumi, A
    Murakami, Y
    Uehara, Y
    MOLECULAR CANCER THERAPEUTICS, 2004, 3 (10) : 1281 - 1288
  • [27] Constitutive Activation of Extracellular Signal-Regulated Kinase and p38 Mitogen-Activated Protein Kinase in B-Cell Lymphoproliferative Disorders
    Toshie Ogasawara
    Masako Yasuyama
    Kiyotaka Kawauchi
    International Journal of Hematology, 2003, 77 : 364 - 370
  • [28] Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders
    Ogasawara, T
    Yasuyama, M
    Kawauchi, K
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2003, 77 (04) : 364 - 370
  • [29] Inhibition of p38 mitogen activated protein kinase increases lipopolysaccharide induced inhibition of apoptosis in neutrophils by activating extracellular signal-regulated kinase
    Sheth, K
    Friel, J
    Nolan, B
    Bankey, P
    SURGERY, 2001, 130 (02) : 242 - 248
  • [30] Activation of the Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Pathway Overcomes Cisplatin Resistance in Ovarian Carcinoma Cells
    Nonaka, Michiko
    Itamochi, Hiroaki
    Kawaguchi, Wakae
    Kudoh, Akiko
    Sato, Seiya
    Uegaki, Kazunori
    Naniwa, Jun
    Sato, Shinya
    Shimada, Muneaki
    Oishi, Tetsuro
    Terakawa, Naoki
    Kigawa, Junzo
    Harada, Tasuku
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (06) : 922 - 929